• Ji-Zhu Liu, Ming Yang, Da-Peng Li, Bin Zhang, Shou-Guo Chen, Chun-Bo Wang, Guang-Yao Li, and Le-Xin Wang.
• Liaocheng People's Hospital and Liaocheng Clinical School of Taishan Medical University, Liaocheng Shandong, P. R. China.
• Clin Invest Med. 2009 Apr 1; 32 (2): E117-23.

PurposeTo evaluate the effect of Haishengsu (HSS) on transplanted K562 and drug-resistant K562/ADM tumors.MethodsMice were inoculated subcutaneously with K562 and K562/ADM cells, respectively. Tumour-bearing animals were divided into HSS, adriamycin, combination therapy (adriamycin plus HSS) and placebo groups. The anti-tumour effect was assessed by tumour growth curve and tumour inhibitory rate (IR).ResultsIn animals inoculated with K562 cells, the inhibitory rates of high (1800mg/kg) and medium (900mg/kg ) dose HSS groups were 100% and 96.4%, respectively, which was higher than that in the adriamycin (88.9%) or the combination therapy groups (85.8%, P < 0.05). The inhibitory rate in the low-dose HSS group (53.4%) was lower than in all other groups (P < 0.01). In mice inoculated with K562/ADM cells, the inhibitory rates in the high, medium and low dose HSS groups were 100%, 95.9%, and 44.1%, respectively. In the adriamycin group, the inhibitory rate was 23.07%, which was lower than in the HSS group (P < 0.01). Pathological examination of tumour tissues from HSS-treated animals showed extensive necrosis and bleeding.ConclusionsHaishengsu inhibits the growth of transplanted K562 tumours in mice. It is also effective in suppressing the growth of drug-resistant K562/ADM tumors in this animal model.

27 keywords...

hide…